JAK2 and acquired polycythemia vera: In PV, post hoc analysis of the RESPONSE trial at 208 weeks has shown a clear and progressive reduction in JAK2 V617F allele burden with continued treatment with average reductions of around one-third achieved in the RUX randomised arm [45].